Product Pipeline

Xel's pharmaceutical product development activities are focused on two key targeted drug delivery fields: Transdermal and Controlled Release. Currently, Xel has developed XEL 001HP, a Huperzine A transdermal patch (a powerful, highly selective and reversible inhibitor of acetyl cholinesterase) for the treatment of Alzheimer's Disease and XEL 002BP, a Bulleyaconitine transdermal patch (a non opioid dependence, long-lasting analgesic agent with anti-inflammation effect) for pain management, both are poised for IND filing in the US. In addition, XEL 001HP has obtained IND approval from Chinese SFDA and a Phase I clinical trial is currently underway in China.

Xel has several drug candidates in preclinical stages as shown below; all of which are currently available for co-development and licensing opportunities:

Product Indication Discovery Preclinical Phase I Phase II Phase III
XEL 001HP
Transdermal Patch
Alzheimer's Disease complete complete
XEL 001HG
Topical Gel
Alzheimer's Disease complete 50%
XEL 002BP
Transdermal Patch
Pain Management/
Anti-Inflamation
complete 100%
XEL 002BG
Topical Gel
Pain Management/
Anti-Inflamation
complete 75%
XEL 002BI
Implant
Pain Management/
Anti-Inflamation
complete 25%
XEL 002LG
Topical Gel
Pain Management/
Anti-Inflamation
complete 50%
XEL 003FP
Nail Lacquer
Anti-fungal
(Onychomycosis)
complete 75%
XEL 003FL
Transdermal Patch
Anti-fungal
(Onychomycosis)
complete 50%
XEL 004FP
Transdermal Patch
Pain Management complete 50%
XEL 005OP
Transdermal Patch
Urology complete 50%
XEL 006LG
Topical Gel
Local Anesthesia complete 50%
XEL 007DO
Oral Tablet
Cadriovascular complete 25%